Andy Morley

Andy Morley is an experienced Chief Scientific Officer at both o2h ventures and o2h group since January 2014, with a focus on project management in drug discovery and medicinal chemistry. In addition, Andy serves as CSO at Opal Oncology Limited since June 2012, developing innovative cancer treatments. Previously, Andy held the position of 3D Fragment Library Project Manager and Medicinal Chemistry Consultant at Andy Morley LTD from September 2011 to December 2013, leading independent projects in medicinal chemistry. A significant tenure at AstraZeneca from August 2000 to September 2011 included roles as Principal Scientist and Team Leader in Medicinal Chemistry. Prior experience includes positions at Aventis and Rhone-Poulenc Rorer, contributing to medicinal chemistry leadership. Academically, Andy obtained a PhD from The University of Salford and completed postdoctoral work at Nagoya University.